Veterinary Orthopedic Medicines Market Size & Growth Forecast 2026–2035, By Segments (Product, Animal Type, Application, Route of Administration, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Veterinary Orthopedic Medicines Market size was around USD 1.87 Billion in 2025 and is slated to grow at a 8.7% CAGR from 2026 to 2035, exceeding USD 4.31 Billion by 2035. The industry revenue for 2026 is calculated at USD 2.01 billion.

• Base Year Value (2025): USD 1.87 Billion
• CAGR (2026-2035): 8.7%
• Forecast Year Value (2035): USD 4.31 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Veterinary Orthopedic Medicines Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 42.61% share in 2025, supported by established companion animal care, greater treatment uptake, specialized veterinary services, and routine orthopedic care across clinical settings.
  • Asia Pacific is projected to grow at a 9.83% CAGR as veterinary infrastructure expands, treatment availability improves, and adoption of orthopedic therapies increases across urban and developing care networks.

• Segment Momentum:

  • Pharmaceuticals lead with 49.29% share in 2025 due to their routine use in managing pain, inflammation, and recovery across diverse orthopedic conditions in standard veterinary practice.
  • Equine is the fastest-growing animal type as horses require specialized, sustained orthopedic care for mobility, lameness, and performance-related joint conditions, increasing targeted therapeutic demand.

• Market Expansion Drivers:

  • Rising prevalence of osteoarthritis and orthopedic disorders in aging pets and animals.
  • Increasing adoption of pet insurance improving access to advanced veterinary treatments.
  • Growth in regenerative therapies including stem cell treatments for animal joint disorders.

• Leading Market Participants:

  Leading players in the veterinary orthopedic medicines market include Zoetis Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Merck & Co., Inc. (United States), Virbac S.A. (France), Vetoquinol S.A. (France), Ceva Santé Animale S.A. (France), Dechra Pharmaceuticals PLC (United Kingdom), Bioiberica S.A.U. (Spain), PetVivo Holdings, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.87 Billion
  • Projected Market Size: USD 4.31 Billion by 2035
  • Growth Forecasts: 8.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Pharmaceuticals (Product) | Canine (Animal Type) | Osteoarthritis (Application) | Injectable (Route of Administration) | Veterinary Hospitals (End Use)
  • Emerging Opportunity Segment: Viscosupplements (Product) | Equine (Animal Type) | Degenerative Joint Disease (Application) | Injectable (Route of Administration) | Veterinary Clinics (End Use)

Market Growth Drivers and Industry Trends

Rising prevalence of osteoarthritis and orthopedic disorders in aging pets and animals

As companion animals live longer and large-animal care becomes more attentive to mobility and productivity outcomes, degenerative joint disease and other musculoskeletal conditions are being diagnosed more frequently, driving demand for the veterinary orthopedic medicines market. This trends treatment patterns from occasional pain management toward longer-term therapeutic use, including anti-inflammatory drugs, adjunctive pain control, and disease-focused interventions that veterinarians incorporate into chronic care plans. The result is not only higher prescription volume but also more regular follow-up, monitoring, and treatment adjustment, which strengthens recurring revenue potential for products positioned around sustained orthopedic management in the veterinary orthopedic medicines market.

Increasing adoption of pet insurance improving access to advanced veterinary treatments

Wider pet insurance uptake changes owner decision-making at the point of care by reducing the out-of-pocket barrier associated with orthopedic diagnostics, surgery support, and extended medical management, aiding market expansion in the veterinary orthopedic medicines market. When reimbursement is available, veterinarians are more able to recommend comprehensive treatment protocols rather than limiting care to basic symptom relief, which increases use of branded analgesics, post-operative medications, and longer-duration treatment regimens. This improves conversion from diagnosis to therapy initiation and increases market penetration for higher-value orthopedic medicines that might otherwise be deferred or declined on cost grounds in the veterinary orthopedic medicines market.

Growth in regenerative therapies including stem cell treatments for animal joint disorders

The emergence of regenerative care is reshaping treatment pathways for chronic joint conditions by moving clinical attention toward earlier intervention, multimodal management, and longer therapeutic engagement, contributing to market size growth in the veterinary orthopedic medicines market. Stem cell treatments and related biologic approaches are rarely used in isolation; they typically sit alongside anti-inflammatory agents, pain medication, and supportive orthopedic care before and after the procedure. That integration strengthens market development by expanding the role of pharmaceuticals around regenerative protocols, while also encouraging specialty clinics and referral centers to build more advanced musculoskeletal treatment offerings tied to the veterinary orthopedic medicines market.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of osteoarthritis and orthopedic disorders in aging pets and animals	2.30%	Moderate	North America, Europe	High	Near Term
Increasing adoption of pet insurance improving access to advanced veterinary treatments	2.00%	Moderate	North America, Europe	High	Near Term
Growth in regenerative therapies including stem cell treatments for animal joint disorders	1.70%	High	Europe, North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 42.61% share of the veterinary orthopedic medicines market. This leadership is underpinned by the region’s well-established companion animal care ecosystem, where diagnosis, surgical intervention, and post-operative pain and joint management are more routinely integrated into veterinary practice. Higher treatment uptake, stronger access to specialized veterinary services, and broader use of advanced orthopedic care in clinical settings keep demand consistently active across both acute injury treatment and longer-term musculoskeletal management.

Asia Pacific is projected to expand at a 9.83% CAGR over the forecast period in the veterinary orthopedic medicines market, bolstered by rising access to veterinary care and increasing treatment adoption for orthopedic conditions in animals. Growth is being impelled by the practical expansion of animal healthcare infrastructure and improving availability of therapies in urban and developing care networks, which is widening the treated patient base. As more owners and care providers move beyond basic care toward structured treatment for fractures, joint disorders, and mobility-related conditions, regional demand is accelerating in a more sustained way.

Key Country Insights

United States

Companion Animal Mobility Care

The U.S. veterinary orthopedic medicines market is shaped by growing demand for treatments that address joint disorders and post-surgical recovery in companion animals. Veterinary practices in the U.S. are increasingly adopting multimodal therapies that improve long-term mobility and quality of life.

Japan

Aging Pet Treatment Demand

Japan's veterinary orthopedic medicines market is influenced by an increasing population of aging companion animals requiring chronic joint care. Veterinary providers in Japan are expanding the use of anti-inflammatory and supportive therapies aimed at maintaining mobility and extending active lifespans.

South Korea

Premium Pet Healthcare Expansion

South Korea is witnessing greater demand for veterinary orthopedic medicines as pet owners seek advanced treatment options for musculoskeletal conditions. Clinics in South Korea are broadening orthopedic care offerings and incorporating specialized therapies into companion animal treatment protocols.

Germany

Advanced Post-Surgical Management

Germany emphasizes veterinary orthopedic medicines that support rehabilitation and pain management following orthopedic procedures. German veterinary clinics are incorporating targeted pharmaceutical therapies alongside advanced surgical interventions to improve recovery outcomes in pets.

France

Integrated Rehabilitation Approach

France is adopting veterinary orthopedic medicines within comprehensive rehabilitation strategies for companion animals. Veterinary professionals in France are emphasizing treatment combinations that manage pain effectively and support functional recovery after injury or orthopedic surgery.

Italy

Small Animal Orthopedic Support

Italy's veterinary orthopedic medicines market is expanding through greater awareness of mobility disorders in dogs and cats. Italian veterinary practices are increasingly using orthopedic medicines as part of long-term management plans designed to improve comfort and daily activity in affected animals.

Segment Leadership and Growth Trends

  Product Segment Analysis: Pharmaceuticals (Largest Segment) vs Viscosupplements (Fastest-Growing Segment)

Pharmaceuticals held the leading position in the veterinary orthopedic medicines market in 2025, accounting for a 49.29% share. This leadership is maintained through their routine use as the first line of treatment for pain, inflammation, and post-procedural recovery across a broad range of orthopedic conditions in animals. In practical veterinary care settings, pharmaceuticals remain deeply embedded in treatment protocols because they are widely prescribed, familiar to clinicians, and applicable across different severity levels, which helps preserve their strong share within the veterinary orthopedic medicines market.

Viscosupplements are emerging as the fastest-growing product segment in the veterinary orthopedic medicines market as treatment decisions increasingly favor joint-focused therapies that can support longer-term mobility management. Their momentum is being shaped by demand for options that fit ongoing osteoarthritis and degenerative joint care, particularly where repeated symptom control and functional improvement are central to treatment goals. Compared with conventional product alternatives that are often used for broader pain management, viscosupplements are gaining traction because they align more directly with the need for targeted orthopedic support in chronic cases.

Animal Type Segment Analysis: Canine (Largest Segment) vs Equine (Fastest-Growing Segment)

Within the veterinary orthopedic medicines market, canine represented the largest animal type segment in 2025 with a 48.87% share. Its leading share reflects the high volume of orthopedic consultations and treatments in dogs, where joint disorders, mobility issues, and injury-related conditions are commonly managed in regular veterinary practice. The canine segment benefits from a broad treatment base that spans companion animal clinics, follow-up care, and ongoing medication use, which keeps demand concentrated and supports its continued leadership in the veterinary orthopedic medicines market.

Equine is the fastest-growing animal type segment in the veterinary orthopedic medicines market, influenced by the need for specialized orthopedic management in horses where mobility and joint performance are closely tied to use, care, and recovery expectations. Growth is being reinforced by increasing attention to structured treatment for lameness, joint stress, and performance-related musculoskeletal issues, areas where orthopedic intervention tends to be more intensive than in many other animal categories. Relative to alternatives, the equine segment is gaining momentum because treatment requirements are often highly targeted and sustained, creating stronger uptake for advanced orthopedic therapies.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Biologics, Viscosupplements, Pharmaceuticals	Pharmaceuticals	Viscosupplements
Animal Type	Canine, Equine, Others	Canine	Equine
Application	Osteoarthritis, Degenerative Joint Disease, Others	Osteoarthritis	Degenerative Joint Disease
Route of Administration	Oral, Injectable, Others	Injectable	Injectable
End Use	Veterinary Hospitals, Veterinary Clinics, Others	Veterinary Hospitals	Veterinary Clinics

Competitive Landscape and Market Positioning

Key companies in the veterinary orthopedic medicines market:

1. Zoetis Inc. (United States)

2. Boehringer Ingelheim International GmbH (Germany)

3. Elanco Animal Health Incorporated (United States)

4. Merck & Co. Inc. (United States)

5. Virbac S.A. (France)

6. Vetoquinol S.A. (France)

7. Ceva Santé Animale S.A. (France)

8. Dechra Pharmaceuticals PLC (United Kingdom)

9. Bioiberica S.A.U. (Spain)

10. PetVivo Holdings Inc. (United States)

Rising awareness of companion animal healthcare is fostering innovation within the veterinary orthopedic medicines market. Research focused on advanced therapeutics and improved pain management solutions is expanding treatment options while addressing the growing demand for effective musculoskeletal care in veterinary medicine.

Industry Development/News

Company Name	Date	Key Development
VetStem	Apr-24	VetStem launched PrecisePRP Canine, an off-the-shelf platelet-rich plasma product for intra-articular administration in dogs. The freeze-dried formulation eliminates the need for blood draws or centrifugation, improving dosing consistency and safety while expanding regenerative orthopedic treatment options in veterinary care.
Felix Pharmaceuticals	Apr-24	Felix Pharmaceuticals received FDA approval for ANADA Carprofen, a nonsteroidal anti-inflammatory drug used to manage pain and inflammation associated with osteoarthritis and post-surgical orthopedic conditions in dogs. The approval strengthens the company’s veterinary pain management portfolio in regulated U.S. markets.
PetVivo Holdings	Oct-23	PetVivo Holdings partnered with Covetrus North America to distribute Spryng with OsteoCushion technology, an injectable device for managing joint pain in animals. The agreement expands U.S. market access and enhances commercial reach through Covetrus’ established veterinary distribution network.
Athersys	Oct-23	Athersys entered a licensing agreement granting Ardent Animal Health exclusive rights to its MAPC stem cell technology for non-human mammal applications in the United States. The deal includes milestone payments and royalties, supporting expansion of regenerative veterinary orthopedic therapies.
Zoetis	Oct-22	Zoetis completed the acquisition of Jurox, an Australian animal health company specializing in veterinary medicines for livestock and companion animals. The acquisition broadens Zoetis’ orthopedic and pain management portfolio and strengthens its global animal health market presence.
Boehringer Ingelheim	Apr-22	Boehringer Ingelheim received European approval for RenuTend, a therapy designed to improve healing of tendon and ligament injuries in horses. The product complements its equine regenerative medicine portfolio and expands treatment options for musculoskeletal conditions in veterinary orthopedics.
Zoetis	Feb-25	Zoetis announced a U.S. label expansion for Librela (bedinvetmab), extending its indication to include broader control of canine osteoarthritis pain. The update enhances treatment accessibility for chronic pain management and strengthens Zoetis’ leadership in monoclonal antibody therapies for veterinary orthopedics.
Ceva Santé Animale	Jan-24	Ceva Santé Animale acquired Scout Bio to strengthen its veterinary regenerative medicine capabilities. The acquisition supports development of advanced biologic therapies targeting orthopedic and chronic conditions in companion animals, expanding Ceva’s innovation footprint in animal health therapeutics.
Movora	Jul-25	Movora signed an exclusivity agreement with B. Braun VetCare’s Aesculap Division to distribute surgical power systems in the United States and Canada. The partnership expands access to advanced orthopedic surgical tools and strengthens Movora’s positioning in veterinary surgical infrastructure markets.
Arthrex	Jun-25	Arthrex launched the Synergy Power System, a battery-powered surgical system featuring ergonomic drill and saw handpieces for orthopedic procedures including sports medicine, trauma, and extremity surgery. The launch enhances surgical efficiency and broadens Arthrex’s veterinary-adjacent orthopedic technology portfolio.